Nanjing Leads Biolabs Co., Ltd. has initiated a Phase II clinical trial for Opamtistomig (LBL-024), a bispecific antibody targeting PD-L1 and 4-1BB, aimed at treating locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. This trial marks a significant step forward, as the current standard of care—PD-1 inhibitors combined with chemotherapy—has shown limited efficacy, with median progression-free survival (PFS) of only 7 months and overall survival (OS) rates ranging from 13 to 17 months. The trial is being led by Professor Shen Lin at Beijing Cancer Hospital and is expected to address the urgent need for more effective treatments in a cancer type characterized by late-stage diagnoses and poor prognoses.

The dual mechanism of Opamtistomig is particularly noteworthy; it not only blocks PD-L1-mediated immune suppression but also activates the 4-1BB co-stimulatory pathway, potentially enhancing T-cell functionality and expanding effector T-cell populations in the tumor microenvironment. This approach aims to provide a more robust and durable anti-tumor response, especially in patients who have shown resistance to existing immunotherapies. Given that gastric cancer is a leading cause of cancer mortality globally, with over 968,000 new cases and 660,000 deaths reported in 2022, the development of Opamtistomig could represent a transformative shift in treatment paradigms.

The implications of this trial extend beyond gastric cancer; Opamtistomig has demonstrated promising results across multiple indications, including non-small cell lung cancer and extrapulmonary neuroendocrine carcinoma. Its unique bispecific design positions it as a potential first-in-class therapy in various malignancies with high unmet medical needs. This advancement could accelerate timelines for drug development in oncology, particularly in immunotherapy-resistant tumor types, and pave the way for new therapeutic strategies that leverage the dual-action capabilities of bispecific antibodies.

Source: globenewswire.com